Launches Pivotal Prostate Cancer Trial
Exelixis Submits Cabo NDA in Medullary Thyroid Cancer
Just in time for the American Society of Clinical Oncology (ASCO) meeting in Chicago, Exelixis Inc. completed the filing of its rolling new drug application (NDA) with the FDA for cabozantinib (XL184) in the lead indication of progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.